Chest
ReviewsBleomycin-Induced Pneumonitis
Section snippets
Clinical Features
Often, BIP starts gradually during treatment, but the development of BIP up to 6 months after discontinuation of bleomycin therapy has also been reported.20 The clinical diagnosis of BIP is rather hampered by its resemblance to other conditions often encountered in cancer patients, such as pneumonia, pulmonary metastases, or lymphangitic carcinoma.
Patients with BIP present initially with a nonproductive cough, exertional dyspnea, and sometimes fever. With progressive pneumonitis, dyspnea at
Pathogenesis
The pathogenesis of BIP has been intensively studied in animals, but data derived from human studies are scarce. In animals, the first event noted is endothelial damage of the lung vasculature accompanied by edema.26 This is followed by influx of inflammatory cells such as macrophages, lymphocytes, and neutrophils into the lung parenchyma and subsequently by fibroblasts leading to pulmonary fibrosis.26 Studies in patients who developed clinically evident BIP showed that alterations in lung
Pulmonary Function Assessments
Numerous methods such as cell counts in BAL fluid, gallium lung scanning, angiotensin-converting enzyme plasma levels, chest radiographs, or CT scans have been evaluated to detect BIP at an early stage, in order to avoid the further development of severe BIP by withholding further treatment with bleomycin.16 Pulmonary function assessments, however, seem to be the most proper tool.
Comis et al48 were the first to show a decrease in the transfer capacity of the lungs for carbon monoxide (Tlco)
Risk Factors
Many studies have been performed to identify risk factors for the development of BIP. However, most of these studies have used different criteria for its diagnosis. Furthermore, for establishing BIP, many studies used lung function assessments that have been shown later not to be specific for BIP when bleomycin is used in a multidrug regimen. In these circumstances and by these lung function assessments, pulmonary toxicity of bleomycin cannot be distinguished from pulmonary effects of other
Prevention and Treatment of BIP
Probably one of the most efficient ways to prevent BIP is to lower the total cumulative dose of bleomycin. Therefore, several studies188283 have been performed in good-prognosis germ-cell cancer to establish the role of bleomycin; these studies showed that bleomycin could not be omitted completely from combination chemotherapy. However, Einhorn et al84 showed that lowering the total dose of bleomycin from 360 to 270 mg does not reduce efficacy of the treatment of good-prognosis disseminated
Conclusion
BIP is a severe and sometimes fatal side effect of bleomycin therapy. Numerous studies have been performed to identify methods capable of detecting BIP at an early preclinical stage. Combined with clinical signs and symptoms, pulmonary function tests reflecting lung volume such as TLC and VC are probably most suitable for this purpose. Identification of risk factors has probably resulted in decreased bleomycin-induced morbidity and mortality, but this has never been examined (to my knowledge).
References (96)
- et al.
Activated bleomycin: a transient complex of drug, iron and oxygen that degradates DNA
J Biol Chem
(1981) - et al.
Bleomycin-induced pulmonary toxicity
Clin Chest Med
(1990) - et al.
Severe bleomycin-induced pneumonitis: clinical features and response to corticosteroids
Chest
(1984) Bleomycin lung damage: the pathology and nature of the lesion
Br J Dis Chest
(1978)- et al.
Interleukin 1 receptor antagonist (IL1-ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica
Cytokine
(1993) - et al.
Oxygen radicals in lung pathology
Free Radic Biol Med
(1990) - et al.
Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity
Toxicology
(1995) - et al.
Bleomycin-induced pulmonary function abnormalities
Chest
(1992) - et al.
Role of pulmonary function tests in the prevention of bleomycin pulmonary toxicity during chemotherapy for metastatic testicular teratoma
Eur J Cancer Clin Oncol
(1982) - et al.
Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating growth factor
Chest
(1997)
Pulmonary complications associated with combination chemotherapy programs containing bleomycin
Am J Med
Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide
Am J Med Sci
Enhanced effects of bleomycin on pulmonary function assessments in patients with decreased renal function due to cisplatin
Eur J Cancer
Pulmonary toxicity after treatment with bleomycin alone or in combination with hyperoxia
Br J Anaesth
Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?
J Urol
Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin's disease: possible synergy
Lancet
The Stanford experience with combined procarbazine, alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease
Ann Oncol
New antibiotics, bleomycin A and B
J Antibiot Ser A
Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models
Clin Cancer Res
Effect of chelating agents and metal ions on the degradation of DNA by bleomycin
Biochem
Properties and products of the degradation of DNA by bleomycin and iron
Biochemistry
Effects of variations in renal function on the clinical pharmacology of bleomycin administrated as an iv bolus
Cancer Treat Rep
Studies on the mechanism of antitumor effect of bleomycin in squamous cell carcinoma
J Antibiot
Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance
Cancer
A fatal hyperpyrexial response to bleomycin following prior therapy: a case report and literature review
Yale J Biol Med
Fulminant hyperpurexia induced by bleomycin
Postgrad Med J
A clinical review of bleomycin: a new antineoplastic agent
Cancer
Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma
Cancer
Bleomycin hypersensitivity pneumonitis
Ann Intern Med
Predictive factors for bleomycin-induced pneumonitis
Am Rev Respir Dis
Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up
Eur J Cancer
Clinical, radiologic and histopathological studies on pulmonary toxicity induced by treatment with bleomycin (N.S.C.-125066)
Cancer Chemother Rep
The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma
J Clin Oncol
Fatal bleomycin pulmonary toxicity in the west of Scotland 1991–95; a review of patients with germ cell tumours
Br J Cancer
Bleomycin: an antitumor antibiotic; clinical experience in 274 patients
Ann Intern Med
Bleomycin-lung: CT observations
Br J Radiol
Ultrastructure of pulmonary bleomycin toxicity
Cancer
The natural course of bleomycin induced pneumonitis (BIP): a follow-up study in eight patients
Am Rev Respir Dis
The pathogenesis of bleomycin-induced pulmonary fibrosis in mice
Am J Pathol
Effective treatment of the pulmonary fibrosis elicited in mice by bleomycin or silica with anti-CD-11 antibodies
Am Rev Respir Dis
Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice
Am J Respir Cell Mol Biol
Essential roles of the Fas/Fas ligand pathway in the development of pulmonary fibrosis
J Clin Invest
Bleomycin stimulation of cytokine secretion by the human alveolar macrophage
Am J Physiol
Lung cytokine production in bleomycin-induced pulmonary fibrosis
Exp Lung Res
Increased expression of transforming growth factor β isoforms (β 1, β 2, β 3) in bleomycin-induced pulmonary fibrosis
Am J Respir Cell Mol Biol
Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-β and procollagen I and III gene expression
Exp Lung Res
Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis
J Exp Med
Induction of tumor necrosis factor-α as a cause of bleomycin-related toxicity
Cancer
Cited by (509)
IL-22 Binding Protein Controls IL-22–Driven Bleomycin-Induced Lung Injury
2024, American Journal of PathologyThe Impact of Bleomycin Deficit on Survival in Hodgkin's Lymphoma Patients: A Retrospective Study
2024, Cancer Treatment and Research CommunicationsEmerging delivery approaches for targeted pulmonary fibrosis treatment
2024, Advanced Drug Delivery ReviewsInsights on the mechanism of bleomycin to induce lung injury and associated in vivo models: A review
2023, International Immunopharmacology